GlassScriptPhysician profile
Mary Collignon
NPI 1194728477
$2,929.99
in general payments reported to CMS, 2019-2025
26 companies · $974 in 2025
The $974 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.32 · 2022: $149 · 2023: $453 · 2024: $1,287 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $572.00 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $536.31 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $373.02 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $253.64 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $231.70 | 2023-2025 | Rexulti |
| Corcept Therapeutics | $141.07 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.31 | 2024-2025 | Caplyta |
| Abbvie INC. | $100.02 | 2024 | |
| Phathom Pharmaceuticals, INC. | $81.61 | 2025 | Voquezna |
| Pfizer INC. | $66.39 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.77 | 2024-2025 | Jardiance |
| Organon LLC | $51.43 | 2022-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $44.57 | 2021-2023 | Vaxelis, Gardasil 9, Rotateq |
| Kowa Pharmaceuticals America, INC. | $32.68 | 2025 | Zoryve |
| Cranial Technologies, INC | $31.87 | 2024 | Doc Band |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $28.50 | 2024 | |
| Phadia US INC. | $25.29 | 2025 | Immunocap |
| Hologic Sales and Service, LLC | $24.69 | 2025 | Aptima, Thinprep 2000 Processor |
| Abiomed | $24.05 | 2025 | |
| Tolmar, INC. | $23.56 | 2025 | Jatenzo |
| Optinose US, INC. | $21.33 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.50 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $18.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.48 | 2022 | |
| Exact Sciences Corporation | $15.55 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $14.47 | 2024 | Trelegy Ellipta, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Collignon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.